Table 2. Association of ePWV With Different End Points in the Patients With Hypertension From SPRINTa.
| Outcome | No. | HR per 1 SD of ePWV (95% CI) | P Value |
|---|---|---|---|
| Primary outcome | 558 | 1.30 (1.17-1.43) | <.001 |
| MI | 212 | 1.10 (0.94-1.30) | .24 |
| Non-MI acute coronary syndrome | 80 | 1.03 (0.78-1.36) | .83 |
| Stroke | 131 | 1.45 (1.20-1.76) | <.001 |
| Heart failure | 162 | 1.70 (1.42-2.04) | <.001 |
| CV death | 100 | 1.39 (1.10-1.76) | .006 |
| Death from non-CV cause | 262 | 1.76 (1.53-2.03) | <.001 |
| All-cause death | 362 | 1.65 (1.46-1.86) | <.001 |
| Primary outcome or death | 750 | 1.36 (1.25-1.48) | <.001 |
Abbreviations: CV, cardiovascular; ePWV, estimated pulse wave velocity; HR, hazard ratio; MI, myocardial infarction; SPRINT, Systolic Blood Pressure Intervention Trial.
a
The model includes Framingham Risk Score, antihypertensive assigned treatment (intensive vs standard), the presence of clinical or subclinical CV disease, antihypertensive treatment at baseline, and systolic blood pressure at baseline and was assessed separately for each outcome.